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Available online 4 February 2016Introduction: Given the importance of β-adrenoceptor signalling in regulating cardiac structure and function, ro-
bust protocols are required to assess potential alterations in such regulation in murine models in vivo.
Methods: Echocardiography was performed in naïve and stressed (isoprenaline; 30 μg/g/day s.c. for up to 14 days)
mice, in the absence or presence of acute β-adrenergic stimulation (dobutamine 0.75 μg/g, i.p.). Controls received
saline infusion and/or injection. Hearts were additionally analysed gravimetrically, histologically and biochemically.
Results: In naïvemice, acute β-adrenoceptor stimulationwith dobutamine increased heart rate, left ventricular (LV)
fractional shortening (LVFS), ejection fraction (LVEF) and wall thickness and decreased LV diameter (p b 0.05). In
stressed mice, dobutamine failed to induce further inotropic and chronotropic responses. Furthermore, following
dobutamine injection, these mice exhibited lower LVEF and LVFS at identical heart rates, relative to corresponding
controls. Sustained isoprenaline infusion induced LV hypertrophy (increased heart weight, heart weight/body
weight ratio, heart weight/tibia length ratio and LV wall thickness (p b 0.05)) by 3 days, with little further change
at 14 days. In contrast, increases in LVEF and LVFS were seen only at 14 days (p b 0.05).
Discussion:Wedescribe protocols for and illustrative data from the assessment ofmurine cardiac responses to acute
and sustained β-adrenergic stimulation in vivo, which would be of value in determining the impact of genetic or
pharmacological interventions on such responses. Additionally, our data indicate that acute dobutamine stimulation
unmasks early signs of LV dysfunction in the remodelled heart, even at a stage when basal function is enhanced.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Methods1. Introduction
Regulation of cardiac function by the sympathetic nervous system is
achieved primarily through the stimulation of cardiac β1-adrenergic re-
ceptors (β1-adrenoceptors, β1-AR), with acute stimulation inducing
rapid and pronounced chronotropic, inotropic and lusitropic effects.
Additionally, sustained β1-adrenoceptor stimulation induces cardiac hy-
pertrophy and remodelling, which may be physiological or pathological
in nature depending on the magnitude and duration of stimulation
(Booysen, Norton, Opie, & Woodiwiss, 2012; Kitagawa, Yamashita, Ito, &
Takaki, 2004; Webb et al., 2010). Such effects of β1-adrenoceptor
stimulation are achieved principally through the activation of cAMP-ceptor; d, end-diastolic; DOB,
ening; HW, heart weight; i.p.,
r septum; LV, left ventricular;
r internal diameter; LVPW, left
us; TL, tibia length; vol, volume.
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. This is an open access article underdependent protein kinase (protein kinase A) isoforms, although activa-
tion of other cAMP effectors, such as members of the exchange protein
directly activated by cAMP (Epac) family, may also contribute in some
cases.
In view of the importance of β1-adrenoceptor signalling pathways in
regulating cardiac structure and function, it is important to have robust
methods to determine how genetic manipulations (e.g. gene knock-out,
knock-in or overexpression), pharmacological interventions (e.g. puta-
tive therapeutic drugs) and cardiac or systemic disease states (e.g. myo-
cardial ischaemia, hypertension, diabetes) inmousemodelsmay impact
on such regulation. In this paper, we describe methods for the in vivo
and ex vivo assessment of the effects of both acute and sustained β1-
adrenoceptor stimulation on cardiac structure and function in wild-
type mice, which may be readily adapted for use in conjunction with
such settings.2. Materials and methods
2.1. Study population
Thirty-four male C57/Bl6J mice (8–10 weeks of age, from Charles
River UK Ltd., Kent, UK) were included in this study and were housedthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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h light/12-h dark regime. Normalmouse chow containing 0.9%NaCl and
water was provided ad libitum. The study was approved by the local
Ethics Review Board and animal handling and experiments were
performed according to the Home Ofﬁce regulations, as detailed in the
Home Ofﬁce Guidance on the Operation of the Animals (Scientiﬁc
Procedures) Act 1986, HMSO (London) and the Guide for Care andFig. 1. Study population and design. Experimental protocols for assessment of cardiac and
adrenoceptor stimulation with ISO and (C) acute β-adrenoceptor stimulation with DOB follow
2-dimensional (B-Mode) images were recorded in parasternal long- (left panel) and short-axi
ventricular level, apical of the posteriomedial papillary muscle in both views. Standard measu
left ventricular posterior wall (LVPW) were performed in systole and diastole in parasternal
during at least three beats from this projection and averaged. Left ventricular anterior wall
short-axis projection.Use of Laboratory Animals by the US National Institute of Health (NIH
Publication 8th edition).2.2. Study design
Three different in vivo protocols were performed.other responses to (A) acute β-adrenoceptor stimulation with DOB, (B) sustained β-
ing sustained β-adrenoceptor stimulation with ISO. (D) For echocardiographic analyses,
s (right panel) projections with guided one-dimensional M-mode recordings at the mid-
rements of inter-ventricular septum (IVS), left ventricular internal diameter (LVID) and
long-axis projection. Left ventricular (LV) cavity size and wall thickness were measured
(LVAW) thickness was determined during at least three beats in systole and diastole in
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As illustrated in Fig. 1A, mice were randomly assigned to receive
a single bolus intraperitoneal (i.p.) injection of dobutamine (DOB,
0.75 μg/g, n = 4) or vehicle (0.9% NaCl, n = 4) at an identical volume.
Echocardiographic and ECG recordings were obtained before and after
the single bolus injection.
2.2.2. Protocol 2: sustained β-adrenergic stimulation
As illustrated in Fig. 1B, mice were randomly assigned to receive a
continuous subcutaneous infusion of isoprenaline (ISO, 30 μg/g/day)
or vehicle (0.9% NaCl) at an identical infusion rate (0.25 μl/h) for 3
(n= 9) or 14 (n= 8) days. Echocardiographic recordings were obtain-
ed before starting and at the end of each infusion period. Additionally,
ex vivo gravimetric and histological analyses were performed on hearts
excised after the 14d infusion period.
2.2.3. Protocol 3: acute β-adrenergic stimulation after sustained
β-adrenergic stimulation
As illustrated in Fig. 1C, mice were randomly assigned to receive
a continuous subcutaneous infusion of isoprenaline (30 μg/g/day,
n = 8) or vehicle (0.9% NaCl; n = 8) at an identical infusion rate
(0.25 μl/h) for 14 days. At the end of the infusion period, mice from
each group were randomly assigned to receive a single bolus i.p. injec-
tion of DOB (75 μg/g, n= 4) or vehicle (0.9%NaCl, n=4) at an identical
volume. Echocardiographic and ECG recordings were obtained before
and after the single bolus injection.
2.3. Echocardiography
All imaging studies were performed using the VisualSonicsVevo®
770 imaging system (Scanhead: RMV707B, 15–45 MHz, cardiac
mouse). Anaesthesiawas induced for oneminute in an induction cham-
ber (3% isoﬂurane mixed with 97% O2 at a ﬂow rate of 1 L/min). After
placing the mouse in a supine position atop a pad with embedded
ECG electrodes, anaesthesia was maintained via inhalation of 1.5–2%
isoﬂurane and 98–98.5% O2 at a ﬂow rate of 1 L/min using a nose
mask. The ECG signal was monitored throughout the procedure. After
immobilising the mouse on the echocardiography stage with tape,
chest hair was removed with hair removal cream and a layer of
preheated ultrasound gel was applied to the chest. Body temperature
was monitored throughout the whole procedure by an inserted rectal
probe and maintained within a narrow range (37.0 °C ± 1.5 °C) via
the heated platform and a heat lamp.
Two-dimensional (B-Mode) images were recorded in parasternal
long- and short-axis projections with guided one-dimensional
M-mode recordings at the mid-ventricular level, apical of the papillary
muscle in both views (Fig. 1D). Standard measurements of inter-
ventricular septum (IVS), left ventricular internal diameter (LVID) and
left ventricular posterior wall (LVPW) were performed in systole and
diastole in parasternal long-axis projection. Left ventricular (LV) cavity
size and wall thickness were measured during at least three beats
from this projection and averaged. Left ventricular anterior wall
(LVAW) thickness was determined during at least three beats in
systole and diastole in short-axis projection (Fig. 1D). LV volume [μl]
LVvol;d [7.0/(2.4 + LVID;d)] * LVID;d3, LVvol;s [7.0/(2.4 + LVID;s)] *
LVID;s3, LV fractional shortening (FS) [%] [(LVID;d - LVID;s)/LVvol;d] *
100 and LV ejection fraction (EF) [%] [(LVvol;d - LVvol;s)/LVvol;d] *
100 were calculated fromM-mode measurements. ECG and respiration
gating were used to suppress movement artefacts.
2.3.1. Dobutamine-stress-test
Dobutamine hydrochloride powder (Sigma-Aldrich, product
number D 0676) was dissolved in ddH2O by gently heating at 37 °C
for 15–20min and vortexing to produce a 10mg/ml DOB stock solution.
DOB working solution (0.1 μg/μl) was prepared by 1:10 dilution of the
stock dilution in sterile 0.9% NaCl. Mice were characterised via baselineechocardiography and ECG, before being randomly assigned to receive
an intraperitoneal (i.p.) single bolus injection of DOB at a dose of
0.75 μg/g body weight or an equivalent volume (7.5 μl/g) of vehicle
(0.9% NaCl). The DOB dose (0.75 μg/g i.p.) was selected on the basis of
preliminary experiments using 3 different doses (0.375 μg/g, 0.75 μg/g
or 1.5 μg/g i.p.), which revealed that 0.75 μg/g was sufﬁcient to trigger
a pronounced cardiac response in a separate cohort of adult C57/Bl6
male mice (data not shown). Echocardiographic B- and M-Mode scans
in long- and short-axis projections and ECG recordings were repeated
immediately after the single bolus injection and then periodically dur-
ing 10 min, until the peak heart rate response was reached and heart
rate began to decline again.
2.4. Osmotic mini-pump implantation
After an acclimatisation period of 7 days, mice were subjected to
subcutaneous implantation of osmotic mini-pumps (ALZET model
1002, Durect Corporation, Cupertino, California, USA; supplied by
Charles River UK Ltd., Kent, UK). After an incision was made on the
back, slightly posterior to the scapulae, a distal subcutaneous pocket
was created and the pump was located posterior to the right ﬂank. ISO
(DL-Isoproterenol hydrochloride, Sigma, St. Louis, MO, USA) was dis-
solved in 0.9% NaCl at a concentration calculated to deliver 30 μg/g/day
for up to 15 days at an infusion rate of 0.25 μl/h. Pumps were ﬁlled
with either the ISO solution or 0.9% NaCl (vehicle) and activated accord-
ing to the manufacturer's instructions. During the surgical intervention,
mice were anesthetised with 3% isoﬂurane mixed with 97% O2 (ﬂow
rate 1 L/min) and the mini-pumps were implanted via a 0.5 cm
interscapular incision under sterile surgical conditions. The wound was
closed with an interrupted suture using a 6–0 silk thread.
2.5. Tissue sampling and processing
At the endpoint of each experiment, mice were anaesthetised with
4% isoﬂurane and subsequently euthanized by cervical dislocation. Fol-
lowing left thoracotomy, the heart was explanted, washed, weighed,
the atria were removed and the ventricular myocardium was split for
biochemical and histological analyses. LV tissue for biochemistry was
immediately frozen in liquid N2 and stored at−80 °C. Midventricular
slices for histological analyses were ﬁxed in 4% formaldehyde within
one minute after explantation of the heart and stored at 4 °C. To assess
tissue congestion, wet and dry weight of lungs, liver, spleen and the left
kidney were determined.
2.5.1. Phosphate afﬁnity SDS/PAGE and immunoblot analysis
For protein analysis of whole cell lysates, LV tissuewas homogenised
and lysed in EDTA-free standard lysis buffer. Samples were resolved by
SDS-PAGE (10% acrylamide) either in standard format or containing
the phosphate afﬁnity reagent PhosTag (40 μmol/L), as described
previously (Candasamy et al., 2014; Kinoshita, Kinoshita-Kikuta, &
Koike, 2009). Prior to transfer of proteins to PVDF membranes, gels
were incubated in transfer buffer containing 1 mmol/L EDTA for
15 min followed by a 15-min incubation in transfer buffer alone for
15 min. Acrylamide-pendant PhosTag was purchased from Wako
Pure Chemical Industries Ltd. (Osaka, Japan), cTnI primary antibody
was purchased from Cell Signaling (Beverly, MA), secondary antibody
and enhanced chemiluminescence reagents were purchased from
GE Healthcare (Buckinghamshire, UK). Expression of bis-, mono- and
un-phosphorylated Troponin I was quantiﬁed using a calibrated densi-
tometer (BioRad GS800).
2.5.2. Histology
Myocardial collagen content (ﬁbrosis) and myocyte cross-sectional
area were assessed following staining with picrosirius red or
haematoxylin and eosin (H&E), respectively, in transversemidventricular
Fig. 2.Acute β-adrenergic response assessed via echocardiography. (A) Representative 1-dimensional echocardiographic long-axis projections of pre (left panel) and post (right panel) i.p.
single bolus vehicle (upper row) or DOB injection (lower row) and corresponding average heart rates. Changes induced by acute i.p. DOB injection in male wildtype mice in regional
dimension of (B) IVS, (C) LVAW and (D) LVPW, (E) LVID and (F) LV volume in end-diastole and end-systole and in (G) LV performance, as assessed by EF, FS and (H) heart rate (displayed
as delta and total values). Vehicle-injected mice served as control. Animal numbers per treatment n = 4; values are shown as mean ± SE, *p b 0.05 vs. vehicle; unpaired student's t-test.
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murine heart tissue, as described previously (Puhl, Muller, et al., 2015).
2.5.3. Data acquisition and statistical analyses
Data acquisition was performed in a blinded manner. Continu-
ous data are presented as mean ± SE. To determine differencesbetween two groups an unpaired student's t-test was applied. Dif-
ferences between four groups were determined by two-way
ANOVA (group comparison involving 2 independent variables,
each one with 2 conditions), followed by Tukey's post-hoc test. All
calculated p-values are two-sided. Differences with a p b 0.05
were considered to be statistically signiﬁcant. All analyses were
64 S.-L. Puhl et al. / Journal of Pharmacological and Toxicological Methods 79 (2016) 60–71performed with Microsoft Excel 2007 and Graph Pad Prism 6.0
software.
3. Results
3.1. Acute β-AR stimulation with dobutamine
Echocardiographic scans and ECG recordingswere performed before
(referred to as “pre injection echo/ECG”) and immediately after the sin-
gle bolus DOB injection and then repeated every 2–3min until the peak
heart rate response was reached (referred to as “post injection echo/
ECG”). Vehicle-injected mice were scanned in an identical manner.
Fig. 2A shows representative 1-dimensional M-Mode scans obtained
from 2 individual mice pre- and post-injection of a single bolus of vehi-
cle or DOB. Pre-injection cardiac phenotypes did not differ between the
groups, as shown in Table 1. For each echocardiographic parameter, the
change (Δ) between pre- and post-injection valueswas calculated in in-
dividual vehicle- and DOB-injected mice and averaged per treatment
group. Compared to vehicle administration, DOB injection evoked a pos-
itive inotropic response that was reﬂected by pronounced regional
thickening of the contracted IVS, LVAWand LVPW (Fig. 2B–D). As a con-
sequence, end-diastolic and end-systolic LVID and LV volume decreased
during the acute β-AR response (Fig. 2E–F). Based on the end-diastolic
and end-systolic LVID measurements, functional parameters such as
EF and FS were calculated (as described in the Methods section).
There was a robust increase in both parameters following DOB injection
but not vehicle injection, conﬁrming a pronounced increase in contrac-
tility following the β-adrenergic stress stimulus (Fig. 2G). As expected,
theDOB-induced inotropic responsewas accompanied by a robust tran-
sient increase in heart rate of approximately 200 bpm (Fig. 2H).
3.2. Sustained β-AR stimulation with isoprenaline
Modest LV hypertrophy could be detected after only 3-days contin-
uous ISO-infusion, as reﬂected by signiﬁcant thickening of IVS, LVAW
and LVPW throughout the cardiac cycle (Fig. 3A–C, p b 0.05). These
structural changes were not accompanied by a decrease in LV cavity
sizes (Fig. 3D–E). Mice infused with ISO for 3 days showed a trend to-
wards increased cardiac function and heart rate, but the difference
from control animals infusedwith salinewas not statistically signiﬁcant
(Fig. 3F–G). Gravimetric analyses (Fig. 4A) revealed a small weight loss
in ISO-infused mice, in contrast to a small weight gain in saline-infused
mice, during the 3-day treatment period. This was accompanied by a
greater lungweight without evidence of congestion (Table 2). In agree-
ment with the echocardiographic evidence of increased LV wall thick-
ness, ISO-infused mice exhibited signiﬁcantly greater heart weight,
heartweight/bodyweight ratio (HW/BW) andheartweight/tibia length
ratio (HW/TL) relative to the saline-infused mice (Fig. 4B; p b 0.05).Table 1
Echocardiographic baseline characterisation before single bolus injection.
Pre-vehicle injection (n = 4) Pre-DOB injection (n = 4)
IVS; d [mm] 0.56 ± 0.03 0.68 ± 0.08
IVS; s [mm] 0.88 ± 0.08 0.85 ± 0.08
LVAW; d [mm] 0.63 ± 0.04 0.64 ± 0.05
LVAW; s [mm] 0.79 ± 0.04 0.87 ± 0.05
LVPW; d [mm] 0.79 ± 0.05 0.71 ± 0.05
LVPW; s [mm] 0.96 ± 0.05 0.94 ± 0.08
LVID; d [mm] 4.20 ± 0.11 3.97 ± 0.04
LVID; s [mm] 3.23 ± 0.16 3.01 ± 0.05
LVvol; d [μl] 78.92 ± 5.00 69.00 ± 1.73
LVvol; s [μl] 42.42 ± 4.85 37.46 ± 1.41
EF [%] 46.74 ± 3.58 45.55 ± 2.37
FS [%] 23.29 ± 2.11 22.38 ± 1.42
Heart rate 421 ± 7 430 ± 7
Data are mean ± SE.After 14-days continuous ISO-infusion, the adaptive remodelling of
the murine heart could be conﬁrmed by thickening of the IVS, LVAW
and LVPW in end-diastole and end-systole (Fig. 5A–C, p b 0.05). This hy-
pertrophic response was not accompanied by an increase in the diastolic
LV cavity size, a feature of maladaptive dilatation, but rather by a signif-
icant decrease in the systolic cavity size, indicating enhanced contraction
(Fig. 5D–E). Indeed, enhanced cardiac performance in the ISO groupwas
reﬂected also by a signiﬁcant increase in EF, FS and heart rate (Fig. 5F–G,
p b 0.05). Continuous ISO infusion for 14 days provoked a gain in body
weight (Fig. 6A). This was accompanied by signiﬁcantly greater weights
of the atria, the lungs and the liver without incidence of congestion
(Table 3). In agreement with the data obtained by echocardiography,
the ISO-induced hypertrophic phenotype was characterised by
signiﬁcant increase in heart weight, heart weight/body weight ratio
(HW/BW) and heart weight/tibia length ratio (HW/TL) (Fig. 6B;
p b 0.05). Consistentwith these observations, ISO-infusedmice exhibited
a signiﬁcant increase in cardiomyocyte cross-sectional area, as assessed
by manually framing H&E stained LV myocytes (Fig. 6C). Determination
of percentage LV collagen content inmid-ventricular tissue slices stained
with Sirius red, as a measure of interstitial ﬁbrosis, revealed no signiﬁ-
cant difference from saline-infused mice (Fig. 6D). Thus, in our model,
sustained ISO infusion evokes a moderate compensated cardiac
hypertrophic phenotype without inducing the hallmarks of maladaptive
remodelling, such as LV dilatation and myocardial ﬁbrosis.
3.3. Acute β-AR responsiveness following sustained β-AR stimulation
In these experiments, DOB or vehicle was administered as a single
bolus injection to mice that had just completed a 14-day period of infu-
sion with saline or ISO. Fig. 7A shows representative 1-dimensional M-
mode echocardiographic scans obtained from individualmice in each of
the 4 study groups. Acute β-adrenergic stimulation with DOB produced
the expected positive inotropic and chronotropic responses inmice that
had received a 14-day infusion of saline (Fig. 7B–C). In contrast, there
was no signiﬁcant dobutamine response in mice that had received a
14-day infusion of ISO (Fig. 7B–C), most likely as a result of the already
elevated basal LV contractility and heart rate observed in such mice
(see also Fig. 5). Nevertheless, when inotropic status following acute
β-adrenergic stimulation with DOB was compared between mice that
had received a 14-day infusion of saline versus ISO, it was notable that
the latter group showed signiﬁcantly lower LVEF and LVFS values at a
similarly elevated heart rate (Fig. 7B–C). These ﬁndings point towards a
deﬁcit in contractile reserve in mouse hearts that had undergone hyper-
trophic remodelling during sustained β-adrenergic stimulation with ISO.
PhosTag SDS/PAGE-immunoblot analysis of the phosphorylation status of
themyoﬁlament protein cardiac troponin I (cTnI) showed that the abun-
dance of bis-phosphorylated (2P) cTnI was increased signiﬁcantly by
DOB in the saline-infused group but not in the ISO-infused group, in
which the abundance of 2P cTnI was already high basally (Fig. 8).
4. Discussion
In the present paper, we describe protocols for and report exemplar
data from the in vivo and ex vivo assessment of murine cardiac
responses to β-adrenergic stimulation in 3 distinct settings:
4.1. Acute β-adrenergic stimulation
For the assessment of cardiac responses to acute β-adrenergic
stimulation, we used dobutamine as the pharmacological stimulus.
Dobutamine is a synthetic sympathomimetic drug that targets primarily
β1-ARs, with weaker agonist effects also at β2- and α1-ARs, and is used
clinically in cardiac stress echocardiography in patients who are unable
to exercise. The use of dobutamine for this application is based on its se-
lective effects on cardiac inotropy and chronotropy with minimal direct
impact on blood pressure. This minimal impact of dobutamine on blood
Fig. 3. Echocardiographic evidence for moderate LV hypertrophy induced by prolonged (3-day) β-AR stimulation. Effect of permanent 3-days s.c. ISO infusion in male wildtype mice on
regional dimension of (A) IVS, (B) LVAW and (C) LVPW, (D) LVID and (E) LV volume in end-diastole and end-systole and on (F) LV performance, as assessed by EF, FS and (G) heart rate.
Saline-infused mice served as control. Animal numbers per treatment n = 9; values are shown as mean ± SE, *p b 0.05 vs. Control; unpaired student's t-test.
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AR stimulation on arterial tone and the agonist's short half-life and thus
transient actions. These characteristics of dobutamine have also led to
its use to assess cardiac responses to acute β-adrenergic stimulation in
pre-clinical studies, including inmice following either intravenous infu-
sion (Dong et al., 2013; Wiesmann et al., 2001; Williams et al., 2001) orintraperitoneal injection (Song et al., 2010; Tyrankiewicz, Skorka,
Jablonska, Petkow-Dimitrow, & Chlopicki, 2013) of the agonist. In
common with previous studies that utilised magnetic resonance
(Tyrankiewicz et al., 2013; Wiesmann et al., 2001; Williams et al.,
2001) or echocardiographic (Dong et al., 2013; Schmid et al., 2015;
Song et al., 2010) imaging of cardiac function in mice, we have found
Fig. 4.Gravimetric evidence for moderate LV hypertrophy induced by prolonged (3-day) β-AR stimulation. Effect of 3-days s.c. ISO infusion inmalewildtypemice on (A) bodyweight and
(B) heart weight as assessed by gravimetric analyses. Saline-infusedmice served as control. Animal numbers per treatment n= 7; values are shown as mean± SE, *p b 0.05 vs. Control;
unpaired student's t-test.
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transient increases in heart rate and LV contractility, the latter reﬂected
by signiﬁcantly greater thickness of the IVS, LVAW and LVPW at end-
systole, as well as increased LVEF and LVFS. Following i.p. administra-
tion of the chosen 0.75 μg/g dose (which was selected on the basis
of pilot experiments that also tested 0.375 and 1.5 μg/g doses), themax-
imum heart rate and contractility responses were achieved by approxi-
mately 5min in each animal, and lasted for up to 15min. This allows the
rapid assessment of cardiac responses to acute β-adrenergic stimulation
under light anaesthesia (1.5–2% isoﬂurane), during which a near-
physiological basal heart rate of around 430 beats/min is maintained,
and permits repeated assessments to be made, for example before and
after a distinct pharmacological or surgical intervention. Based on the
variability of the cardiac responses to dobutamine in our experiments
in naïve animals, we can also make recommendations regarding the
group sizes that may be necessary to assess the impact of these inter-
ventions, as well as genetic manipulation, on such responses. ForTable 2
Effects of short-term (3d) ISO infusion on organ weights.
Organ Weight (mg)
Control (n = 7) ISO (n = 7)
Atria Wet 9.4 ± 1.0 11.4 ± 0.3
Lungs Wet 133.4 ± 3.9 152.4 ± 3.9⁎
Dry 32.2 ± 1.1 36.1 ± 1.2⁎
Liver Wet 1212 ± 73 1059 ± 96
Dry 429 ± 26 353 ± 35
Spleen Wet 77.1 ± 2.7 95.9 ± 14.5
Dry 19.1 ± 0.7 23.7 ± 3.4
Kidney Wet 149.0 ± 6.2 152.0 ± 7.9
Dry 40.2 ± 1.6 40.6 ± 1.8
Data are mean ± SE.
⁎ p b 0.05 vs. Control.example, on the basis of our data, an experimental group size of ≥4
would be necessary to detect a 20% change in the dobutamine-
induced increase in LVFS, with an alpha error of 5% and a power of
80%. Our detailed description of protocols and illustrative data from
the bolus administration of a rationally selected dose of dobutamine
through the i.p. route (which does not require invasive vascular access)
provides guidance for the ready assessment of cardiac responses to
acute β1-AR stimulation in mice under light anaesthesia, in near-
physiological conditions.
4.2. Sustained β-adrenergic stimulation
Cardiac responses to sustained β-adrenergic stimulation were
assessed at both 3 and 14 days after the start of the continuous s.c. infu-
sion of isoprenaline. Isoprenaline, a synthetic non-selective β-AR ago-
nist that targets both β1- and β2-ARs, is commonly used to induce
persistent adrenergic stress on the heart in rodent models, particularly
when studying the pathogenesis and consequences of β-AR-mediated
cardiac remodelling (Booysen et al., 2012; Kitagawa et al., 2004; Kudej
et al., 1997; Webb et al., 2010). A particular advantage of isoprenaline
over dobutamine for this application is the absence in the former of
α1-AR agonist activity, which itself can induce cardiac hypertrophy
(Milano et al., 1994; O'Connell et al., 2003; Puhl, Kazakov, et al., 2015)
There are, however, sporadic reports in the literature reporting the car-
diac remodelling effects also of sustained systemic administration do-
butamine in rats (Buttrick, Malhotra, Factor, Geenen, & Scheuer, 1988)
and mice (Anderson, Moore, & Larson, 2008). In our experiments, the
s.c. infusion of isoprenaline at a dose of 30 μg/g/day inducedmarked car-
diac hypertrophy at 14 days after the start of infusion, as reﬂected by
signiﬁcant increases in the thickness of the IVS, LVAW and LVPW at
end-diastole (as well as end-systole), the HW/BW and HW/TL ratios,
and cardiomyocyte size. Importantly, the phenotype that we observed
seemed to reﬂect the development of compensatory hypertrophy,
Fig. 5. Echocardiographic evidence for LV hypertrophy induced by sustained (14-day) β-AR stimulation. Effect of sustained 14-days s.c. ISO infusion in male wildtype mice on regional
dimension of (A) IVS, (B) LVAW and (C) LVPW, (D) LVID and (E) LV volume in end-diastole and end-systole and on (F) LV performance, as assessed by EF, FS and (G) heart rate.
Vehicle-infused mice served as control. Animal numbers per treatment n = 8; values are shown as mean ± SE, *p b 0.05 vs. Control; unpaired student's t-test.
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dilatation or signiﬁcant myocardial ﬁbrosis, and LVEF and LVFS were
signiﬁcantly enhanced, at this time point. While this observation is con-
sistent with a previous report utilising the sustained s.c. administration
of isoprenaline in mice through an osmotic mini-pump (Schmid et al.,2015), other studies have noted evidence of maladaptive remodelling
following persistent β-AR stimulation or over-expression (Grimm
et al., 2015; Webb et al., 2010; Wiesmann et al., 2001; Yan et al.,
2015). Such differences in ﬁndings may be a consequence of the use of
different doses or durations of isoprenaline treatment (of note, in
Fig. 6.Morphological evidence for moderate LV hypertrophy induced by sustained (14-day) β-AR stimulation in the absence of myocardial ﬁbrosis. Effect of continuous 14-days s.c. ISO
infusion inmale wildtypemice on (A) bodyweight, (B) heart weight as assessed by gravimetric analyses, (C) cardiomyocyte cross-sectional area and (D) percentage LV collagen content,
as assessed via histological analyses. Saline-infusedmice served as control. Animal numbers per treatment n= 8 if not indicated otherwise; values are shown as mean± SE, *p b 0.05 vs.
Control; unpaired student's t-test.
Table 3
Effects of sustained (14d) ISO infusion on organ weights.
Organ Weight (mg)
Control (n = 8) ISO (n = 8)
Atria Wet 8.6 ± 0.8 12.1 ± 0.7⁎
Lungs Wet 142.2 ± 3.8 168.6 ± 3.8⁎
Dry 33.2 ± 0.8 38.6 ± 0.7⁎
Liver Wet 1150 ± 84 1351 ± 10⁎
Dry 360 ± 10 422 ± 10⁎
Spleen Wet 76.1 ± 3.6 78.5 ± 3.1
Dry 18.4 ± 0.9 18.7 ± 0.7
Kidney Wet 141.7 ± 4.6 152.7 ± 4.6
Dry 36.4 ± 1.2 38.2 ± 1.0
Data are mean ± SE.
⁎ p b 0.05 vs. Control.
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prenaline (Tang et al., 2013; Yan et al., 2015) or longer treatment pe-
riods (Booysen et al., 2012) were used), and different mouse strains
and/or ages. Interestingly, in the present study, our echocardiographic
and gravimetric analyses of cardiac structure and function after only
3 days of isoprenaline infusion indicated that the development of com-
pensatory hypertrophy occurs predominantly within this time-frame
after the initiation of continuous β-adrenergic stimulation. These obser-
vations suggest that investigation of the initial triggering pathways and
mechanisms underlying β-AR-mediated compensatory hypertrophy
should be focused on the initial hours and days following the start of iso-
prenaline infusion. Once again, based on the variability of the cardiac re-
sponses to sustained isoprenaline infusion in our experiments in naïve
animals, we can make recommendations regarding the group sizes
that may be necessary to assess the impact of pharmacological, surgical
or genetic manipulations on such responses. As an example, our data
Fig. 7. Echocardiographic evidence for loss of contractile reserve following sustained (14-day) β-AR stimulation, revealed by subsequent acute β-AR stimulation. (A) Representative 1-
dimensional echocardiographic long-axis projections of saline-infused (Control) and ISO-infused (ISO) wild-type mice pre (left panel) and post (right panel) i.p. single bolus vehicle or
DOB injection and corresponding average heart rates. Effects of acute i.p. DOB injection (DOB) in saline-infused (Control) and ISO-infused (ISO) wildtype mice on (B) LV function, as
assessed by EF and FS, and (C) heart rate. Vehicle-injected mice served as control. Animal numbers per treatment n = 4; values are shown as mean ± SE, *p b 0.05 vs. corresponding
vehicle, +p b 0.05 vs. corresponding control, two-way-ANOVA with Tukey's post-test.
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crease in the HW/BW ratio at the 3-day time point, with an alpha
error of 5% and a power of 80%, an experimental group size of ≥4
would be necessary.
4.3. Acute β-adrenergic stimulation after sustained β-adrenergic stimulation
To explore the potential of acute β-adrenergic stimulation to reveal
any deﬁcits in cardiac function in remodelled hearts, which may not
be apparent in the basal state, we also examined the effects of a single
bolus injection of dobutamine following a 14-day infusion of isoprena-
line. Indeed, the application of the dobutamine stress-test revealed
that a loss of contractile reserve is present even at a stage of compensa-
tory hypertrophy that is accompanied by elevated basal cardiac func-
tion. The mechanisms underlying such a deﬁcit cannot be determined
on the basis of the present study, but may include abnormalities in ex-
citation–contraction coupling, sarcomeric protein function, myocardial
perfusion (for example, through reduced capillary density) or metabo-
lism. Nevertheless, the desensitisation of cardiac β-ARs seems anunlikely causal factor since the heart rate of the ISO-infused animals
was maintained at an elevated level basally (637 ± 1 bpm) and was
comparable to that of saline-infused animals following dobutamine in-
jection (611 ± 12 bpm). This suggestion is supported at a biochemical
level by our observations on the phosphorylation status of cTnI, whose
bis-phosphorylation by protein kinase A (PKA) downstream of β1-AR
stimulation is a key mechanism regulating cardiac twitch dynamics
(Pi, Kemnitz, Zhang, Kranias, & Walker, 2002). Our data show that the
abundance of bis-phosphorylated (2P) cTnI was elevated in ISO-
infused mice relative to saline-infused mice and was comparable to
that observed in saline-infused mice following dobutamine injection.
This indicates the presence of a functional β1-AR/PKA signallingmodule
in the myocardium of ISO-infused mice. Of note, using magnetic reso-
nance imaging, Wiesmann and colleagues (Wiesmann et al., 2001)
have previously reported analogous ﬁndings, by showing that the
acute i.p. administration of dobutamine helps unmask evidence of dia-
stolic dysfunction in a distinct mouse model of compensatory cardiac
hypertrophy without abnormalities in basal LV function (4-month-old
transgenic mice with cardiac-speciﬁc overexpression of the β1-AR).
Fig. 8. Biochemical evidence of myoﬁlament protein phosphorylation following sustained
(14-day) β-AR stimulation and subsequent acute β-AR stimulation Effects of acute i.p.
DOB injection (DOB) in saline-infused (Control) and ISO-infused (ISO) wild-type mice
on the relative the abundance of non-phosphorylated (0P), mono-phosphorylated (1P)
and bis-phosphorylated (2P) cTnI relative to the sum of bis-, mono- and un-
phosphorylated moieties. (A) Representative PhosTag phosphate afﬁnity SDS-PAGE and
standard SDS-PAGE immunoblots. (B) Quantitative data on the abundance of bis-
phosphorylated (2P) cTnI, as a percentage of total cTnI (sum of the signals from all 3
cTnI phospho-moieties). Vehicle-injected mice served as control. Animal numbers per
treatment n = 4; values are shown as mean ± SE, *p b 0.05 vs. vehicle-injected Control,
two-way-ANOVA with Tukey's post-test.
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(Wiesmann et al., 2001) indicate that assessment of the cardiac effects
of the acute i.p. administration of dobutamine in the closed-chest
mouse under light anaesthesia is a valuable method that may reveal
contractile deﬁcits arising from distinct pharmacological, surgical or ge-
netic interventions that are not apparent under basal, unstressed
conditions.
To conclude, in thepresent paper, we describe detailedmethodology
for and provide illustrative data from the assessment of the functional
and structural cardiac responses to acute and sustained β-adrenergic
stimulation in mice in vivo, which we hopewill be helpful to cardiovas-
cular investigators in assessing the potential impact of pharmacological,
surgical or genetic interventions on such responses in pre-clinical
studies.
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